THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS
A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high. We present results of the cost-consequence analysis of combination therapy with f...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2017-09-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/565 |
| _version_ | 1826563770670907392 |
|---|---|
| author | S. L. Pavlinsky P. I. Shabalkin |
| author_facet | S. L. Pavlinsky P. I. Shabalkin |
| author_sort | S. L. Pavlinsky |
| collection | DOAJ |
| description | A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high. We present results of the cost-consequence analysis of combination therapy with fulvestrant and palbociclib compared to fulvestrant monotherapy or combination of exemestan and everolimus as a second-line therapy for metastatic breast cancer. It was shown that the combination therapy involving palbociclib increased the length of quality-adjusted life by 191 days and overall survival by almost a year. The use of palbociclib increased the length of quality-adjusted life by 0.06 QALY compared to the combination arm consisting of everolimus. The cumulative 10 year cost per patient was equal to 5.3 million rubles for combination therapy with palbociclib and 3.5 million rubles for combination therapy with everolimus. |
| first_indexed | 2024-04-10T01:53:40Z |
| format | Article |
| id | doaj.art-cafd72be1e604a4583345df42385251f |
| institution | Directory Open Access Journal |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| last_indexed | 2025-03-14T10:09:15Z |
| publishDate | 2017-09-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj.art-cafd72be1e604a4583345df42385251f2025-03-02T11:16:09ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682017-09-01164192510.21294/1814-4861-2017-16-4-19-25463THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSISS. L. Pavlinsky0P. I. Shabalkin1I.I. Mechnikov North-Western State Medical University.N.N. Blokhin Russian Cancer Research Center.A new generation of aromatase inhibitors and target therapy directed at cycline-dependent kinases 4 and 6 gives a new opportunity to treat metastatic breast cancer. However, the cost of innovative therapy remains high. We present results of the cost-consequence analysis of combination therapy with fulvestrant and palbociclib compared to fulvestrant monotherapy or combination of exemestan and everolimus as a second-line therapy for metastatic breast cancer. It was shown that the combination therapy involving palbociclib increased the length of quality-adjusted life by 191 days and overall survival by almost a year. The use of palbociclib increased the length of quality-adjusted life by 0.06 QALY compared to the combination arm consisting of everolimus. The cumulative 10 year cost per patient was equal to 5.3 million rubles for combination therapy with palbociclib and 3.5 million rubles for combination therapy with everolimus.https://www.siboncoj.ru/jour/article/view/565qalycost-consequence analysisinhibitor of cycline-dependent kinases 4/6inhibitor of mammalian target of rapamycinmetastatic breast cancer |
| spellingShingle | S. L. Pavlinsky P. I. Shabalkin THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS Сибирский онкологический журнал qaly cost-consequence analysis inhibitor of cycline-dependent kinases 4/6 inhibitor of mammalian target of rapamycin metastatic breast cancer |
| title | THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS |
| title_full | THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS |
| title_fullStr | THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS |
| title_full_unstemmed | THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS |
| title_short | THE USE OF PALBOCKLIB, A CYCLINE-DEPENDENT KINASE 4/6 INHIBITOR, IN THE TREATMENT OF METASTATIC BREAST CANCER. A COST-CONSEQUENCE ANALYSIS |
| title_sort | use of palbocklib a cycline dependent kinase 4 6 inhibitor in the treatment of metastatic breast cancer a cost consequence analysis |
| topic | qaly cost-consequence analysis inhibitor of cycline-dependent kinases 4/6 inhibitor of mammalian target of rapamycin metastatic breast cancer |
| url | https://www.siboncoj.ru/jour/article/view/565 |
| work_keys_str_mv | AT slpavlinsky theuseofpalbocklibacyclinedependentkinase46inhibitorinthetreatmentofmetastaticbreastcanceracostconsequenceanalysis AT pishabalkin theuseofpalbocklibacyclinedependentkinase46inhibitorinthetreatmentofmetastaticbreastcanceracostconsequenceanalysis AT slpavlinsky useofpalbocklibacyclinedependentkinase46inhibitorinthetreatmentofmetastaticbreastcanceracostconsequenceanalysis AT pishabalkin useofpalbocklibacyclinedependentkinase46inhibitorinthetreatmentofmetastaticbreastcanceracostconsequenceanalysis |